- Home
- POCI vs INKT Comparison
POCI vs INKT Comparison
Compare POCI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POCI
- INKT
- Stock Information
- Founded
- POCI 1982
- INKT 2017
- Country
- POCI United States
- INKT United States
- Employees
- POCI N/A
- INKT N/A
- Industry
- POCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INKT Medicinal Chemicals and Botanical Products
- Sector
- POCI Health Care
- INKT Health Care
- Exchange
- POCI Nasdaq
- INKT Nasdaq
- Market Cap
- POCI 35.1M
- INKT 28.8M
- IPO Year
- POCI N/A
- INKT 2021
- Fundamental
- Price
- POCI $4.96
- INKT $62.86
- Analyst Decision
- POCI
- INKT Strong Buy
- Analyst Count
- POCI 0
- INKT 2
- Target Price
- POCI N/A
- INKT $37.50
- AVG Volume (30 Days)
- POCI 17.1K
- INKT 2.4M
- Earning Date
- POCI 05-15-2025
- INKT 08-12-2025
- Dividend Yield
- POCI N/A
- INKT N/A
- EPS Growth
- POCI N/A
- INKT N/A
- EPS
- POCI N/A
- INKT N/A
- Revenue
- POCI $17,626,155.00
- INKT N/A
- Revenue This Year
- POCI N/A
- INKT N/A
- Revenue Next Year
- POCI N/A
- INKT N/A
- P/E Ratio
- POCI N/A
- INKT N/A
- Revenue Growth
- POCI N/A
- INKT N/A
- 52 Week Low
- POCI $3.47
- INKT $4.56
- 52 Week High
- POCI $6.59
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- POCI 62.07
- INKT 57.39
- Support Level
- POCI $4.62
- INKT $6.80
- Resistance Level
- POCI $5.10
- INKT $7.88
- Average True Range (ATR)
- POCI 0.32
- INKT 0.40
- MACD
- POCI 0.02
- INKT 0.02
- Stochastic Oscillator
- POCI 90.48
- INKT 58.86
About POCI Precision Optics Corporation Inc.
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.